Home
overview

Now running for almost two decades, SMi Group are delighted to announce the return of its 17th annual Pain Therapeutics conference, taking place on the 22nd - 23rd May 2017 in London, and featuring a half day post-conference workshop on the 24th May!

 

Aimed at an audience of scientific leaders and senior specialists in neuroscience, CNS, clinical operations and pharmacology, the 17th annual show will provide a focal point for the industry to assess new innovations in effective and safe pain management.

Created with an expert advisory board, this year's programme will feature a selection of carefully handpicked keynote addresses and case studies to capture the latest developments and novel approaches in pain therapy and drug development. It will home in on key topics such as: product formulation; opioid addiction; translational pain research; breakthroughs in drug discovery; advantages and limitations of animal models; and present exclusive new findings from phase II clinical trials.

 

Download a brochure to take a look at the packed agenda for 2017! 

 

  • Awareness of new guidelines on the clinical development of medicinal products intended for the treatment of pain
  • Strategies and real case studies to minimise risk of opioid dependence
  • Evaluate the translation gap with case studies from a pre-clinical and clinical perspective
  • Explore the latest in the area of neuropathic pain, with the latest case studies from top pharma companies
  • Examine the use of animal models to study pain pathways

 

Join our growing community of scientific and industry pain experts. Previous attendee's included:

 

Asahi Kasei Pharma Corporation; Astellas Pharma; Biogen Idec Ltd; Cellectricon; Centre for Human Drug Research; Chromocell Corporation; Clarivate Analytics; Deallus Consulting Ltd; Ethypharmrt; Galapagos; GlaxoSmithKline; Glenmark Pharmaceuticals Limited; Grunenthal Gmb H; Grunenthal Gmbh; GSK; Imperial College London; INSTITUT DE RECHERCHE PIERRE FABRE ; Korea Institute of Science and Technology; Levicept; MD Biosciences; Merck & Co.; Nektar Therapeutics; Novartis; Orion Pharma ; Pfizer; Pharmaleads; PRA Health Sciences; Reckitt Benckiser; Regeneron Pharmaceuitcals Inc; The Lewisham Hospital N H S Trust; The University Of Sheffield; University College London; University Of Strathclyde; VIAJES EL CORTE INGLES; Wollongong Hospital; Zoetis;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Session Opening Remarks

Anthony Jones

Anthony Jones, Professor of Neuro-Rheumatology, University of Manchester
View Bio

9:10 Challenges in the development of novel pain treatment options

Theo Meert

Theo Meert, Head of Global Government Grant Office, Janssen Pharmaceutica NV
View Bio

  • Conflicts in pain research
  • Conflicts in economic value
  • Conflicts in using compound
  • Opioid addiction

     

  • 9:45 CGRP receptor antagonists for the treatment of migraine

    Ian Bell

    Ian Bell, Principal Scientist, MSD, USA
    View Bio

    10:20 Morning Coffee

    10:50 The utility of early pharmacodynamics testing in pain drug development

  • Failure rate of new analgesic compounds in phase II is notoriously high. Determining pharmacodynamic effects of novel drugs in healthy subjects prior to moving to patient studies can reduce risk by proving pharmacology and aiding in dose selection
  • We performed three studies with three different potentially analgesic compounds in healthy subjects, using the PainCart, a multimodal pain test battery
  • Each of the studies had a randomized 4- or 5-way cross-over design and was double-blind, placebo- and active comparator controlled
  • The compounds that were tested included GABA-A receptor agonist, a pan-Trk inhibitor, and a selective Nav1.7 sodium channel blocker. The positive controls were pregabalin and ibuprofen
  • The studies were performed in parallel to phase II studies in patients and aimed to test the correlation between efficacy of the compounds in evoked pain test models and efficacy in patients with clinical pain
  • Results of each of the three PainCart studies will be presented at the meeting

     

     

  • Geert Jan Groeneveld

    Geert Jan Groeneveld, Research Director, Centre for Human Drug Research
    View Bio

    Richard Butt

    Richard Butt, CEO, Apollo Therapeutics
    View Bio

    11:30 Patient stratification based on somatosensory phenotyping: Implications for mechanism-based pain treatment and drug development

    Thomas Klein

    Thomas Klein, Associate Director Translational Science, Mundipharma Research
    View Bio

    12:05 Networking Lunch

    13:15 Brain mechanisms of vulnerability and resilience to pain: Who controls the magic?

    Anthony Jones

    Anthony Jones, Professor of Neuro-Rheumatology, University of Manchester
    View Bio

  • What happens in the brain when we are in pain?
  • What makes us more or less susceptible to pain?
  • How can we use this information to understand current treatments and develop new brain-based therapies?
  • 13:50 Chairman's Session Opening Remarks

    Steven Kamerling

    Steven Kamerling, Therapeutic Area Head for Pain, Inflammation and Oncology, Zoetis
    View Bio

    13:55 Tissue repair in neuropathic pain: the translation from humans to rodent models

    Mary Hannaman

    Mary Hannaman, President, NeuroDigm
    View Bio

    Many humans with neuropathic pain lack clinical evidence of a specific lesion, nerve injury or disease. Animal models currently used in screening for analgesics do not mimic these patients. The physiologic dichotomy between the human patients and the rodent models has led to failures in the development of effective new treatments.

  • Consideration of the rodent’s age in the analgesic response
  • Time after injury alters the effectiveness of an analgesic
  • Tissue Remodeling creates a temporal window to study the initiation and maintenance of neuropathic pain
  • 14:35 The advantages and challenges in using pigs for assessment of new pain therapy

    Sigal Meilin

    Sigal Meilin, CSO, MD Biosciences
    View Bio

  • The high similarity in the structure and function of both swine and human skin suggests the pig as the chosen model for topical and local analgesic drug development
  • The swine as the ideal translational model: Testing drug candidates in swine models de-risks clinical trials and potentially prevents unexpected failures
  • Enabling the assessment of PK/PD and wound healing in the same animal
  • 15:15 Afternoon Tea

    15:45 How veterinary trials inform human analgesic drug development

    Steven Kamerling

    Steven Kamerling, Therapeutic Area Head for Pain, Inflammation and Oncology, Zoetis
    View Bio

    The assessment and alleviation of pain in companion animals is an important component of veterinary medicine. Companion dogs spontaneously develop painful diseases similar to those in humans, such as osteoarthritis, cancer, and neuropathies.  An increasing number of human pharmaceutical companies are turning to veterinary medicine for proof of concept studies to assess novel drug targets

  • What are the similarities in pain states between dogs and humans and how are they assessed?
  • What veterinary trials have been conducted on novel pain therapies and how have they informed human drug development?
  • What advantages and disadvantages do veterinary trials have compared to preclinical assessment in rodent pain models?
  • 16:20 Translational pain research

    Thomas Christoph

    Thomas Christoph, Head of Pharmacology and Biomarker Development, Grunenthal GmbH
    View Bio

    A growing number of clinical candidates for the treatment of pain failed in clinical POC. How does the industry react to decrease attrition?

  • Potential and limitations of animal studies
  • From animals to human tissue
  • How to improve our screening tools
  • 16:55 Improving the translatability of neurophysiological pharmacodynamic biomarkers in pain pathways

    Keith  Phillips

    Keith Phillips, Senior Research Scientist, Lilly UK
    View Bio

    17:30 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Joseph Stauffer

    Joseph Stauffer, Chief Medical Officer, Cara Therapeutics, Inc.
    View Bio

    9:10 A New Path to Pain Relief: Time for Change with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)

    Joseph Stauffer

    Joseph Stauffer, Chief Medical Officer, Cara Therapeutics, Inc.
    View Bio

    9:45 NKTR-181: Separating analgesia from euphoria in a novel opioid agonist for chronic pain

    Stephen Doberstein

    Stephen Doberstein, Senior Vice President and Chief Scientific Officer, Nektar Therapeutics
    View Bio

    Traditional mu-opioid agonists can have excellent analgesic properties, but are typically associated with high abuse liability that can lead to addiction and dependence.  Recent research has associated the rate of molecular entry across the blood brain barrier with increased abuse liability in preclinical species.  Novel opioids that have greatly reduced rates of entry into the CNS separate the euphorigenic effects from the analgesic effects of CNS receptor engagement, raising the prospect of an inherently low-abuse liability opioid analgesic, independent of formulation or route of administration.

  • Drugs of abuse: Relationship of brain entry rate to euphoria and reinforcing behavior
  • Engineering brain entry rate of MOR agonists to reduce euphoria and abuse liability
  • Preclinical analysis of brain transport rate, dopamine release, and reinforcing behavior
  • Clinical analysis of human abuse liability of NKTR-181, a novel opioid agonist with inherently slow CNS entry
  • 10:20 Morning Coffee

    10:50 Prescription drug abuse – a critique of abuse deterrent technologies

    Aia Malik

    Aia Malik, Product Manager - Healthcare, Lucideon
    View Bio

    Overview of the abuse deterrent formulation (ADF) landscape

  • Need for ADF technologies - what’s the issue?
  • Benefits, risks and drawbacks - for patients and industry
  • Regulatory and governmental pressures
  • Comparison of the available and developing technologies:

  • Do they avert insufflation, intravenous abuse and manipulation via solvent extraction?
  • Will they jeopardise ease of use and compliance by innocent and in-need patients?
  • Will it really make a difference?
  • Future requirements and opportunities for ADF

    11:30 Enhancing endogenous opioid concentrations as a novel treatment for severe pain

    Tanja Ouimet

    Tanja Ouimet, Head of Clinical Operations, Pharmaleads
    View Bio

    12:05 Exploiting synergy in the neurotrophin pathway to provide analgesia

    Iain Chessell

    Iain Chessell, Head of Neuroscience, AstraZeneca
    View Bio

    12:40 Networking Lunch

    13:50 Considerations on advancing a novel analgesic pipeline

    Randall Stevens

    Randall Stevens, Chief Medical Officer, Centrexion Therapeutics Corp.
    View Bio

    The current set of analgesics available to patients has been inadequate to manage chronic pain. The inadequacies stem from both insufficient efficacy, as well as substantial risks in these analgesics use for chronic pain. Development of novel, non-opioid analgesics that match the safety and efficacy requirements of indications improves the drugs’ utility and likelihood of technical success

  • Risk: Benefit in matching drug and target to appropriate indications and populations
  • Utility of Big Data analytics in identifying indications for novel analgesics
  • Case Study of CNTX-4975 development in Morton’s Neuroma and Knee Osteoarthritis
  • 14:25 Using patient reported outcome measures to improve the management of pain (PROMs)

    Shaloo Pandhi

    Shaloo Pandhi, Global Program Medical Director, Novartis
    View Bio

    15:00 Afternoon Tea

    15:30 Drug development to patients: What does the road look like?

    Karin Hygge Blakeman

    Karin Hygge Blakeman, Head of Medical Affairs Nordics, Grunenthal Sweden AB
    View Bio

  • Therapy areas and patient selection
  • Market and marketing
  • Legislation and access
  • 16:05 Potassium channels as pain and migraine targets: Challenges and path forward

    Narender Gavva

    Narender Gavva, Scientific Director, Amgen
    View Bio

  • Nociceptive pathways
  • K+ channels and pain signaling
  • Voltage-gated K+ channels
  • Two pore domain channels
  • 16:40 Exploring the biology of botulinum neurotoxin for treatment of chronic pain

    Mikhail Kalinichev

    Mikhail Kalinichev, Director, in vivo Neurology, Ipsen Innovation
    View Bio

  • Botulinum neurotoxin is a protein complex produced by bacterium Clostridium botulinum
  • Its mechanism of action, prevention of neurotransmitter release, has been used successfully in the clinic to treat muscle and glandular hyperactivity disorders and some forms of chronic pain
  • The exact mechanisms of neurotoxin-induced reduction in chronic pain remain unknown
  • Preclinical studies in rodents suggest that reduction in pain is not linked to the muscle-relaxant properties of neurotoxins and may involve central mechanisms

  • 17:15 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Iain Chessell

    Iain Chessell

    Head of Neuroscience, AstraZeneca
    Joseph Stauffer

    Joseph Stauffer

    Chief Medical Officer, Cara Therapeutics, Inc.
    Randall Stevens

    Randall Stevens

    Chief Medical Officer, Centrexion Therapeutics Corp.
    Stephen Doberstein

    Stephen Doberstein

    Senior Vice President and Chief Scientific Officer, Nektar Therapeutics
    Theo Meert

    Theo Meert

    Head of Global Government Grant Office, Janssen Pharmaceutica NV

    Aia Malik

    Product Manager - Healthcare, Lucideon
    Aia Malik

    Aia Malik is Lucideon’s Healthcare Product Manager. Lucideon is a provider of novel drug delivery and formulation technologies for the pharmaceutical industry. Aia pursues new technology and service offerings to benefit Lucideon’s clients. She helps to ensure that Lucideon is at the forefront of new technologies and that it has an in-depth understanding of its markets, thus helping its clients to grow and prosper. Aia holds a BSc (Hons) Forensic Science (First Class Honours) and joined the company originally as part of Lucideon’s chemical analysis team.

    Anthony Jones

    Professor of Neuro-Rheumatology, University of Manchester
    Anthony Jones

    Anthony Jones is professor of Neuro-rheumatology at Manchester University and leads the Human Pain Research Group. He is a consultant rheumatologist at Salford Royal Foundation Trust. He has established one of the first multidisciplinary inflammatory arthritis clinics in the North West for patients with complex needs. He has also established a multidisciplinary musculoskeletal pain clinic for patients with rheumatic pain and a neuropathic pain for patients with nerve-damage related pain. In order to work more closely with healthcare professionals in primary care, the musculoskeletal and neuropathic pain clinics have recently moved to the Walkden Gateway Centre. This new facility integrates the highest standards of clinical practice with opportunities for involvement in leading-edge research.

    Whilst at the Hammersmith Hospital Professor Jones pioneered the development of techniques to image neurochemical and metabolic brain responses to pain using Positron Emission Tomography. Over the last twenty years he has used a number of functional brain imaging techniques to understand the normal and abnormal mechanisms of pain perception. There is now the exciting prospect of using some of the insights gained in these studies to develop new approaches to pharmacological and cognitive interventions for chronic pain. He also leads the International Association for the Study of Pain Musculoskeletal Pain Taskforce, and has led the development of National and International Guidelines on the Integrated Management of Musculoskeletal Pain (jointly sponsored by the BSR and the IASP).
    His main current goals are to use the current understanding of pain perception to encourage more rational use of current therapies and to develop new mechanisms-based treatments for pain.

    Geert Jan Groeneveld

    Research Director, Centre for Human Drug Research
    Geert Jan Groeneveld

    Dr. Groeneveld was trained as a Neurologist at the University Medical Center Utrecht where he also performed his PhD. Before joining CHDR, he worked among others on gene therapy projects at biotechnology company Genzyme. Since 2009 he is Research Director at the Centre for Human Drug Research (CHDR) in Leiden, and is responsible for research in the areas of neurology and pain. At CHDR he was trained as a clinical pharmacologist. He is also a staff-member at the department of Neurology of VU University Medical Center, Amsterdam, where he performs clinical work as a neurologist and is involved in the multidisciplinary care for patients with pain. His primary scientific interest is in early phase drug development for the treatment of pain and neurodegenerative diseases. He is a treasurer of the working group for Pain of the Dutch Neurological Society, vice-chairman of the Dutch Journal for Neurology and Neurosurgery and executive editor to the British Journal of Clinical Pharmacology.

    Iain Chessell

    Head of Neuroscience, AstraZeneca
    Iain Chessell

    Dr. Iain Chessell is the Head of the Neuroscience Innovative medicines unit at AstraZeneca, based in Cambridge UK, leading a cross-functional team dedicated to discovery and clinical development of the neuroscience portfolio.
    Dr. Chessell joined the AstraZeneca (AZ) subsidiary, MedImmune, in November 2008 as vice president, Research, with the intent of initiating neuroscience R&D at MedImmune. After building a portfolio in analgesia and neurodegeneration, in 2010 he was promoted to vice president and head of the Neuroscience Center of Excellence (CoE) and subsequently head of the AstraZeneca neuroscience innovative medicines unit. Dr Chessell also serves on the AstraZeneca IMED leadership team which has responsibility for running the AZ’s discovery and early development organization.
    Prior to joining AZ, Dr. Chessell was chief executive officer at NeuroDiscovery where he completed a number of Phase 1 and Phase 2 clinical programs for analgesia. Previously, he was global head of pain R&D for GlaxoSmithKline, where he delivered a portfolio of clinical candidates, and was involved in 19 clinical development projects from Phase 1 to Phase 3. He was also responsible for review of potential in-license opportunities, and was chair of the core disease teams for pain and neurodegeneration, as well as serving as chair of the Neurology management team. Dr. Chessell also managed several high profile academic and industrial collaborations, and is author of more than 95 peer reviewed publications.
    Dr. Chessell received his bachelor’s degree in pharmacology from University College London, and received his doctoral degree from the Department of Neurochemistry at the Institute of Neurology, London.

     

    Ian Bell

    Principal Scientist, MSD, USA
    Ian Bell

    Ian M. Bell was educated at Cambridge University and received an M.A. in Natural Sciences (1988) and a Ph.D. in Organic Chemistry (1991). He was awarded a NATO postdoctoral fellowship to continue his studies at the Scripps Research Institute in La Jolla, CA, working in the lab of Prof. Donald Hilvert. In 1994 he joined MSD in West Point, PA, where he is currently a Principal Scientist in the Department of Discovery Chemistry. He has worked on a number of programs in the areas of neuroscience, oncology and infectious diseases, including CGRP receptor antagonists for the treatment of migraine.

    Joseph Stauffer

    Chief Medical Officer, Cara Therapeutics, Inc.
    Joseph Stauffer

    Dr. Stauffer is an executive physician and Chief Medical Officer (CMO) at Cara Therapeutics. He is also the Founder of Alta Life Sciences, LLC., a boutique pharmaceutical/investment consulting firm. Prior to joining CARA he served as CMO in both public and private specialty pharma companies. From 2004-2009 he was CMO at Alpharma Pharmaceuticals; and the architect of the clinical development program for EMBEDA, the first abuse-deterrent long-acting opioid analgesic approved by the FDA (see www1.pfizerpro.com/hcp/embeda/technology). His medical practice and clinical research experience spans over 20 years; having built teams of clinicians, scientists, MSLs, regulators and safety experts in support of clinical development projects, marketed brand drugs and devices.
    Joe began his industry career as Global Medical Director at Abbott Laboratories. In that role he was responsible for Phase I-III trials. Prior to Abbott he worked at FDA as a Medical Review Officer in the Anti-Inflammatory & Analgesic Division of the Center for Drug Evaluation and Research. While there, he reviewed Investigational New Drug (IND) Applications and New Drug Applications (NDA) for opiate, non-opiate, anti-inflammatory, topical and novel pain compounds. Disease areas included: rheumatoid/osteo/psoriatic arthritis, AS, PHN, DPN, post-operative, acute/chronic pain, Multiple Sclerosis and other rare painful diseases.
    Dr. Stauffer practiced clinically for eight years, first as a Navy general medicine physician and then as an Anesthesiologist. He completed residency training in Anesthesiology & Critical Care Medicine at the Johns Hopkins University Hospital and maintains an appointment as part-time Assistant Professor in the Department of Anesthesiology and Critical Care Medicine at the Johns Hopkins University School of Medicine. He received his MBA from a joint program (TRIUM) between New York University, Stern School of Business, London School of Economics (LSE) and HEC (Hautes Etudes Commerciales) School of Management in Paris. Dr. Stauffer is a veteran of the US Navy; honorably discharged as a Lieutenant Commander after serving eight years, including a 3-yr.active duty tour as a Naval Medical Officer delivering primary and acute care to soldiers, sailors, marines, dependents and retirees. He graduated from the Philadelphia College of Ostoepathic Medicine and carries an active Pennsylvania State medical license.
    He is a 2002 founding member of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT). In 2011, under the FDA’s Critical Path Initiative, this collaboration became an official public-private partnership between pharma, FDA, NIH, academia and patient advocacy associations. The new group, Analgesic Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) is an ongoing multi-year effort designed to address the major gaps in scientific information which confound analgesic clinical trials and analgesic drug development. He has lectured internationally on topics ranging from clinical drug development, medical affairs, investor relations and the FDA regulatory process.
    In 2005 he served as an expert member of the FDA/Mayo Clinic Working group on Patient Reported Outcomes and co-authored the supportive paper (Value in Health, Nov/Dec 2007) on validation of self-reported outcome measures. This consortium presented their consensus to the FDA at an open meeting in February 2006 as part of the rollout of the FDA Guidance for Industry, Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.
    He has served as a manuscript reviewer for Mayo Clinic Proceedings (2006) , Pain Medicine (2014), and Therapeutic Advances in Drug Therapy (2014) In 2007 he was named one of the “100 Most Inspiring People” by PharmaVOICE magazine. In 2011 he was selected as a Board member of the American Academy of Pain Medicine Foundation. From 2014-2015 he served on the Board of Directors of TrialScope, a provider of technology enhanced clinical trial solutions and services.
    In 2012 the European Commission appointed him as an expert clinical research reviewer as part of the European Union (EU) health initiative for Research & Innovation. He was invited back in 2014 to continue this work for the EU 'Health, Demographic Change and Wellbeing' Horizon 2020 project.

     

    Karin Hygge Blakeman

    Head of Medical Affairs Nordics, Grunenthal Sweden AB
    Karin Hygge Blakeman

    Dr Hygge Blakeman has worked in the pain field for almost two decades, with more than 10 of those years in the pharmaceutical industry. Starting in preclinical discovery, moving to translational science into the medical sciences, Karin brings experience from the many different steps of a drug’s way to the market.
    Dr Hygge Blakeman received her Ph.D. in Neurophysiology from the Karolinska Institute in 2002 for studies on spinal mechanisms of pain. She moved on to do a post doc with AstraZeneca and then joined them to lead a team focused on pre-clinical models of analgesia and in vivo pharmacology. In 2010, she joined a team of preclinical and clinical scientists to form the Translational Sciences Department, were she was responsible for analgesia biomarkers in project stages from idea to clinical trials. Since 2015 she is a part of the medical department at Grunenthal Nordics, focusing on introducing new pain treatments to physicians.

    Keith Phillips

    Senior Research Scientist, Lilly UK
    Keith  Phillips

    Dr Keith Phillips is a senior research scientist within the Neuroscience group at the Lilly UK research park in Windlesham Surrey leading a in vivo neurophysiology group supporting the development of translatable biomarkers for both pain and neurodegeneration projects. His group specialises in electrophysiological recordings in anaesthetised and awake behaving animals in peripheral nerves, spinal cord and centrally using both single unit and EEG/LFP recording techniques. Though close collaborations with early stage clinical groups internally, external academic and industry collaborator he is involved in a number of clinical translational projects. Keith is the Lilly lead within the Horizon2020 IMI pain group and is leading a new IMI project aiming to clinically validate a number of neurophysiological pain biomarkers. He has led a number of internal exploratory projects and also worked on multiple projects that have delivered clinical candidates. Prior to joining Lilly, Keith completed is PhD in neuroscience at Cardiff University and then continued his research at Bristol University as a postdoc within Dr Matt Jones group. He received his bachelor’s degree in pharmacology from Southampton University.

    Mary Hannaman

    President, NeuroDigm
    Mary Hannaman

    Mary Hanaman MD is founder and president of NeuroDigm Corp. She is board certified in Physical Medicine and Rehabilitation and Pain Medicine with over thirty years active clinical experience with treatment of neuromuscular injuries, spinal cord injuries, amputations, neurological disorders, and degenerative conditions. Her clinical focus is on the neuroanatomic diagnosis and localized treatment of subacute and chronic pain conditions associated with these disparate disorders. She has extensive experience with therapeutic peripheral nerve blocks. NeuroDigm’s preclinical research translates her clinical experience into a model of neuropathic pain as a tissue matrix disorder. She is a graduate of Baylor College of Medicine and is on the adjunct staff at the University of North Texas Health Science Center in the Department of Integrative Physiology as an assistant research professor.

    Mikhail Kalinichev

    Director, in vivo Neurology, Ipsen Innovation
    Mikhail Kalinichev

    Dr. Mikhail Kalinichev has more than 15 years of broad, multi-functional experience in pharmaceutical industry, specializing in therapeutic areas of neurology and psychiatry. Currently, he is a Director of the in vivo Neurology/Toxins unit at Ipsen Innovation, France. Previously, Mikhail worked at Lundbeck pharmaceuticals (Denmark), Addex Therapeutics (Switzerland) and GlaxoSmithKline (UK). Mikhail obtained a doctorate (Ph.D.) in Behavioral Neuroscience from the Center for Molecular & Behavioral Neuroscience, Rutgers University (USA). He has published more than 40 scientific publications. Mikhail is a recipient of the GlaxoSmithKline Exceptional Science Award and the Vernalis Prize of the British Association for Psychopharmacology.

    Narender Gavva

    Scientific Director, Amgen
    Narender Gavva

    Drug discovery leader, has a 17-yr strong record of planning, completing programs and delivering clinical candidates. Group leader, mentors junior scientists, cross functional and cross-site team leader (both small molecule and antibody programs) with an excellent track record to plan and complete research programs. Member of the sr. staff, licensing evaluation teams, and efficiency initiatives. Experienced in full drug discovery cycle including validation of targets, HTS assays, automation, hit/lead identification, lead optimization, clinical candidate selection, and represented research on clinical teams. Extensive drug discovery leadership experience in ion channels, GPCRs, transporters, kinases, and transcription factors toward identifying clinical candidates. Leading an in vitro pharmacology group that supports assay development, focused screens, lead optimization efforts, evaluation of new technologies and automated HTS.
    Gave invited lectures, presentations at several scientific conferences (APS, EB, SBS, Spring Pain Research, IBC ACT, Arrowhead pain, etc). Authored and published 49 papers in research areas of drug discovery, lead optimization, pharmacology, clinical trials, molecular biology, biochemistry, and gene regulation. Serves as an ad hoc reviewer for several journals (AJP, JBC, JBS, JCI, J. Neurosci, JPET, Mol. Pharm, Pain & others).

    Randall Stevens

    Chief Medical Officer, Centrexion Therapeutics Corp.
    Randall Stevens

    Randall Stevens, M.D. joined Centrexion Therapeutics as the Chief Medical Officer in April 2015. Randall is a board certified internist and rheumatologist with more than 25 years in pharmaceutical medicine. Prior to joining Centrexion, he served as the Corporate Vice President, Head of Inflammation and Immunology Clinical Development of Celgene Corporation. Earlier in his career, Randall spent 11 years at F. Hoffmann La Roche where he was a global leader in inflammation and immunology clinical research. In total, Randall has played an integral role in bringing five drugs to market. Additionally, he is Clinical Professor of Medicine at Robert Wood Johnson School of Medicine and on the faculty since 1987.

    Richard Butt

    CEO, Apollo Therapeutics
    Richard Butt

    Richard is CEO of Apollo Therapeutics, a collaborative venture between three world-leading UK universities (Imperial College London, UCL and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). Apollo provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.
    Richard is a cell biologist with a degree in biochemistry from the University of York and PhD from University College London and prior to Apollo spent 20 years in pharmaceutical drug discovery and development. Richard developed his technical experience and leadership skills in leading biology teams, drug safety teams and for the last few years leading clinical translational strategy in the Pain and Neuroscience therapy area. Richard has lead 7 programmes to clinical candidate selection, developed IND/CTA-enabling and preclinical regulatory packages for many assets, and led >30 clinical studies spanning Ph0 to Ph2 designs, execution and delivery.

    Shaloo Pandhi

    Global Program Medical Director, Novartis
    Shaloo Pandhi

    Shaloo Pandhi, physician by training holds MD in Clinical Pharmacology. She has over 10 years of experience in global drug development in several therapeutic areas. She is working currently as Global program medical director at Novartis Pharma AG Switzerland. In her role she is responsible for clinical leadership of development program for a novel molecule targeted for neuropathic pain treatment.

    Sigal Meilin

    CSO, MD Biosciences
    Sigal Meilin

    PhD and post Doc in Neurobiology and Neurochemistry. Subject of research were multi-parametric monitoring of the living brain under oxygen stress and the cross talk between the immune system and the neuronal system in neurodegenerative disease. When joining the industry years ago I lead the pharmacology department of Pharmos. The main R&D focus at that time was developing cannabinoid agonist for the treatment of neurodegenerative diseases and pain. For the last 10 years I have the honor of leading the science at MD Biosciences and MD Biosciences Innovalora. The company focus is in neurology pain inflammation and cancer.

    Stephen Doberstein

    Senior Vice President and Chief Scientific Officer, Nektar Therapeutics
    Stephen Doberstein

    Steve Doberstein joined Nektar in January 2010 as Senior Vice President and Chief Scientific Officer to lead discovery research at Nektar. Dr. Doberstein brings over 20 years of experience in biotechnology research and development to the company. Prior to joining Nektar, Dr. Doberstein served as Vice President of Research at XOMA, Five Prime Therapeutics, and Xencor, and held a variety of senior positions at Exelixis. His experience spans small molecule, protein therapeutics, and monoclonal antibody discovery and development in therapeutic areas including oncology, neuroscience, inflammation, immunology, and metabolic diseases. Dr. Doberstein also serves as the Chairman of the Board of Nektar India.
    Dr. Doberstein received his Ph.D. in Biochemistry, Cell and Molecular Biology from the Johns Hopkins University School of Medicine where he studied in the laboratory of Dr. Thomas Pollard, and completed his postdoctoral work in Dr. Corey Goodman's laboratory at UC Berkeley. Earlier in his career, Dr. Doberstein held a variety of engineering roles at DuPont after receiving his B.S.Ch.E. degree in Chemical Engineering from the University of Delaware.

    Steven Kamerling

    Therapeutic Area Head for Pain, Inflammation and Oncology, Zoetis
    Steven Kamerling

    Steve is a Registered Pharmacist and received his Pharmacy degree from Drake University. He then pursued graduate studies in Pharmacology and received a PhD from the College of Medicine at the University of Illinois. Steve became a postdoctoral fellow in Pharmacology at the University of Kentucky, College of Medicine from, later becoming a Research Associate in Veterinary Sciences. His research at the time focused on in vivo neuropharmacology of pain transmission and opioid and nicotine pharmacology. Subsequently, Steve joined the faculty of the School of Veterinary Medicine at Louisiana State University and achieved the rank of Endowed Professor at the time of his departure. He subsequently joined the Pharmacia & Upjohn Company (later becoming Pfizer then Zoetis) to pursue a career in drug discovery and has continued in that capacity since 1999. Steve is currently Therapeutic Area Head of Pain & Inflammation, Oncology, Cardiac Disease and Oncology. Steve’s research interests include animal models of pain, arthritis, inflammation, heart disease and the pharmacology of novel analgesics, NSAIDs, opioids and sedatives. He has also been active in evaluating novel, molecularly targeted therapeutics in spontaneous canine neoplasias, from a translational medicine perspective. Steve enjoys playing jazz guitar and singing in his free time.

    Tanja Ouimet

    Head of Clinical Operations, Pharmaleads
    Tanja Ouimet

    Having completed her thesis on serine proteases in learning mechanisms at the Institute of Clinical Research of Montréal, Tanja joined the laboratory of J.C. Schwartz in Paris in 1996 where she pursued her research on metalloproteases for 10 years. Her work was published in highly respected journals, and her vast experience of proteases provided her with a solid international reputation in the field. She joined Pharmaleads in 2006 to head the Biochemistry laboratory, characterizing metalloprotease and inhibitor activity in vitro and in vivo, through the design of specific assays. In 2014, she was appointed head of clinical operations.

    Theo Meert

    Head of Global Government Grant Office, Janssen Pharmaceutica NV
    Theo Meert

    Prof Theo F Meert is the head of the R&D Global Government Grant office (G3O) of J&J. The G30 aims to be a Center of Excellence and point of contact for Public Private Partnerships and grants worldwide by ensuring optimal use of available (public) funding opportunities to optimize our strategic engagement in PPPs as an important tool in our external innovation strategies for Janssen Pharmaceutica, MD&D and J&J consumers. Besides being a point of contact for multiple grant agencies, Theo is an active member in EFPIA, IMI and various strategic government groups such as the SGG DKM and ND, and the point of contact of various local & international agencies.
    During his career at J&J, started in 1981, he is appointed to multiple international global functions. He was born in 1958 in Oostham, and obtained a Ph.D.on psychopharmacology in Experimental Psychology at the University of Brussels (1986) and a Ph.D. in Medicine/Anesthesiology at the University of Antwerp (1994).
    Within his various functions obtained within J&J up to senior Research Fellow, he guided different multidisciplinary research teams within the field of CNS (Psychiatry- Addiction -Pain –Neurology/ Alzheimer). The activities of these groups covered the complete drug discovery process from early TI/TV over drug candidate selection to POC and further clinical testing. Dr Meert also supports some Full Development products and is involved in the scientific support of novel and marketed products. He was a key driver for several advanced projects in the CNS area leading to marketed drugs and has constructed an extensive network within J&J and external scientific and clinical organizations. Later on, he did built up an external network on external partnership initiatives and was instrumental in various novel external innovation models
    His scientific expertise is reflected in multiple patents (>15), publications (> 225), congress communications (> 200) and invited lectures (>150). He is professor and scientific advisor/researcher at different universities (Leuven (Dept Biological psychology), Antwerp (Dept Pharmac Biomed Vet Sciences), Brussels (VUB, Dept Biolog Psychology), Hasselt (Dept Med Biomed sciences) and Ghent (Fac Medicine and Health sciences, dept. Anesthesiology), (co)promoter of various mainly (bio)medical PhD students.

    Thomas Christoph

    Head of Pharmacology and Biomarker Development, Grunenthal GmbH
    Thomas Christoph

    Thomas Christoph has over 20 year experience within the pharmaceutical industry working in preclinical pharmacology. At Nycomed he contributed to the development of Lornoxicam (Xefo®). At Grünenthal he has 20 year experience in pain pharmacology overseeing a large spectrum from classical opioids such as buprenorphine (Norspan®) and tramadol (Tramal®) to innovative analgesics such as tapentadol (Palexia®) and cebranopadol up to cutting edge novel targets like ion channels. His group is deeply involved in developing novel pain read-outs and in translational aspects of pain research actively searching for pre-competitive networks within different frameworks such as EU-based or local/regional co-operations. Numerous full papers, abstracts and patents document his scientific work.

    Thomas Klein

    Associate Director Translational Science, Mundipharma Research
    Thomas Klein

    Dr. Klein, MD, is a board-certified physiologist trained at the University of Mainz, Germany. Before joining Mundipharma Research in 2012, he performed his PhD in Neurophysiology under the guidance of Prof. Rolf-Detlef Treede at the Neurophysiology Department of the University of Heidelberg (Medical Faculty Mannheim), with a research focus on translational human pain models of neurogenic sensitization. As a member of the German Research Network on Neuropathic Pain (DFNS), he was also involved in the development of clinical somatosensory phenotyping techniques, such as a standardized Quantitative Sensory Testing (QST) battery.
    At Mundipharma Research he is responsible for translational science aspects in pain and other CNS diseases.

    Sponsors and Exhibitors

    Official Media Partner

    Official Publication

    Supporters

    Workshops

    Animal Models of Pain: A Critical Assessment
    Workshop

    Animal Models of Pain: A Critical Assessment

    Copthorne Tara Hotel
    24th May 2017
    London, United Kingdom

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    An Interview with Tanja Ouimet, Head of Clinical Operations at Pharmaleads

    Download

    Pain 2017 Preliminary list of attendee's

    Download

    PainCart: a multi-modal, standardised test battery

    Download

    Sponsors and Exhibitors


    Centre for Human Drug Research

    Sponsors and Exhibitors
    http://www.chdr.nl/

    Since 1987, CHDR has developed into a unique research organisation specialising in early phase studies which combines knowledge and academic collaborations with operational excellence in clinical trial services. CHDR's strong track record in analgesic and pain research allows us to offer an efficient route towards proof of concept in patients.


    MD Biosciences

    Sponsors and Exhibitors
    http://www.mdbiosciences.com

    MD Biosciences AAALAC accredited Preclinical Services Laboratories provide exclusive, in-depth studies in the core areas of immunology, inflammatory diseases and neurology. Pain and neurodegenerative diseases form the core of our strong CNS and neurological studies area. MD Biosciences is an industry leader in the development of pig translational models for the study of pain. Studies are accompanied by a host of in vitro methodologies including multiplex protein analysis, qPCR, flow cytometry, histology and immunohistochemistry, offering the opportunity to investigate mode of action of candidate drugs.


    NeuroDigm Corp

    Sponsors and Exhibitors
    http://www.neurodigm.com/

    NeuroDigm translates clinical insights into a refined nonsurgical animal model of neuropathic pain, the NeuroDigm GEL model. By mimicking soft tissue repair the GEL model embodies a new platform for studying the physiology of persistent neural pain and the chronic use of opiates.

    Media Partners


    ACNR

    Official Media Partner
    http://www.acnr.co.uk

    ACNR (Advances in Clinical Neuroscience & Rehabilitation) is one of the most widely read publications in the neurology field in the UK. It provides concise review articles, specialist reviews of core papers from international journals, conference news, book reviews, short accounts of best management practice, case reports, news of awards/appointments and more. This independently produced journal is available free of charge to members of the profession, and we welcome your input.

    Media Partners


    Pain News

    Official Publication
    https://www.britishpainsociety.org/pain-news-1/

    The British Pain Society Newsletter Pain News is published quarterly and is edited by Dr Arasu Rayen. Members of the Society will receive a free copy and are encouraged to contribute to the content.


    The British Journal of Pain

    Official Publication
    http://bjp.sagepub.com/

    The British Journal of Pain is the official journal of the British Pain Society. It provides scientists and clinicians in pain medicine with peer-reviewed review articles and expert opinions on all aspects of pain management from basic science to its clinical application including pain physiology, pharmacology and interventions. This journal provides content of multidisciplinary interest and reviews and forecasts important issues and trends in the management of acute and chronic pain.

    Media Partners


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. We are an online R&D matching tool that connects Scientifics and organizations involved in discovery, development and delivery of new healthcare products with service and products providers worldwide. Life science information technology is undergoing a revolution. Part of that revolution involves new, unexplored business models, open innovation, open data and collaboration. If you have a project or idea that you would like to propose, develop or run, we can help. A New Collaboration Network Model for Discovery Research and Development • Effective Platform: the 95% • 5.000 registered users // > 15.000 Newsletter subscribers • Geographical background: 45,5% Europe / 37,5% North America / 16,5% Asia / 0,5% ROW • Professional background: Outsourcing Manager, Project Manager, CEO, Business Developer, CSO, Account Manager, Sales & Marketing People, Scientists, R&D. For further information, please visit our website www.contract-biotechnology.com


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    European Biotechnology Network

    Supporters
    http://european-biotechnology.net/

    The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe. The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.


    BioChem Adda

    Supporters
    https://www.biochemadda.com/

    BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!


    Technology Networks

    Supporters
    http://www.technologynetworks.com

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Copybook - Pharmaceutical

    Supporters
    http://www.copybook.com/pharmaceutical

    Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions? SIGN UP FOR FREE today! Copybook – Your Global Business Network


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Labhoo

    Supporters
    http://www.labhoo.com



    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    BioPharm Insight

    Supporters
    http://www.biopharminsight.com

    BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.